Cardiovascular Research · 2006 · 157 citations · 44 references
Life SciencesCardiologyMolecular BiologyGene ExpressionGene TherapyVirologyGene Delivery VectorsIn Vivo Gene DeliveryLocal Gene DeliveryViral Gene ExpressionViral TranscriptionAdeno-associated Viral VectorsAdenoviral VectorsAdenovirus VectorsLuciferase ReportersTherapeutic Gene TransferViral Vector DeliveryViral Vector PromotersViral Vectors
OBJECTIVE: Vectors based on recombinant adeno-associated virus 2 (AAV-2) are a promising tool for cardiac gene transfer. However, potential therapeutic applications need to consider the predominant transduction of the liver once AAV-2 vectors enter the systemic circulation. We therefore aimed to increase efficiency and specificity of cardiac vector delivery by combining transcriptional and cell surface targeting. METHODS: For analysis of transcriptional targeting, recombinant AAV vectors were generated harboring a luciferase reporter gene under control of the cytomegalovirus (CMV) promoter or the 1.5-kb cardiac myosin light chain promoter fused to the CMV immediate-early enhancer (CMV(enh)/MLC1.5). Luciferase activities were determined in representative organs three weeks after intravenous injection of the vector into adult mice. Transductional targeting was studied using luciferase-reporter constructs crosspackaged into capsids of AAV serotypes 1 to 6 and modified AAV-2 capsids devoid of binding their primary receptor heparan sulfate proteoglycan. RESULTS: Intravenous injections of AAV-2 vectors harboring the CMV(enh)/MLC1.5 promoter enabled a specific and 50-fold higher reporter gene expression in left ventricular myocardium of adult mice compared to vectors containing the CMV promoter. Comparison of AAV-2 vector genomes crosspackaged into capsids of AAV-1 to -6 showed that AAV-1, -4, -5, and -6 capsids increased cardiac transduction efficiency by about 10-fold. However, transduction of other organs such as the liver was also increased after systemic administration. In contrast, AAV-2-based vectors with ablated binding to their primary receptor heparan sulfate proteoglycan enabled a significantly increased efficiency of cardiac gene transfer and reduced transduction of the liver. CONCLUSIONS: Combining transcriptional targeting by the CMV(enh)/MLC1.5 promoter and AAV vectors devoid of binding the AAV-2 primary receptor results in an efficient cardiac gene transfer with a significantly reduced hepatic transduction.
44
A Light and Electron Microscopic Study
Sydney S. Schochet, William F. McCermick, Gerald F. F · 1976 · 1.6K citations
Medicine, Cell Biology, Physics +5
A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus
Michael Boshart, Friedemann Weber, Gerhard Jahn et al. · Cell · 1985 · 1.2K citations
Joseph E. Rabinowitz, Fabienne Rolling, Chengwen Li et al. · Journal of Virology · 2002 · 750 citations · Full text